Testing CMS-D017 in Healthy Volunteers
Part of Blood & lymphatic clinical trials.
This trial tests a new investigational drug called CMS-D017 in healthy volunteers. Researchers will give single and multiple doses to see how the body processes it and if it's safe. You could help find an important new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old.
- Have a body mass index (BMI) between 19.0 and 26.0, and weigh at least 45 kg if female or 50 kg if male.
- Be generally healthy, with no significant medical conditions or recent serious illnesses.
- Not be pregnant, nursing, or planning pregnancy (or sperm/egg donation) for 3 months after the study.
- Agree to avoid alcohol, caffeine, grapefruit, strenuous exercise, and certain medications during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new drug, HSK39297, works in people with mild to moderate liver impairment (Child-Pugh A or B). It compares them to healthy volunteers to see how the liver affects the drug's safety and how the body processes it.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
Hear when a new Complement-mediated Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.